Stem Cells Group, EXOCOBIO are dominating the Global Exosome Therapeutic Market in 2018

Global Exosome Therapeutic Market is expected to grow at a healthy CAGR of 21.9% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below:

Access Full Report at https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market

Global exosome therapeutic market is an upcoming market which includes key players and local players. The market is growing to the favourable market scenario. The market has a prominent growth in upcoming years due to increasing geriatric population.

Stem Cells Group dominated the exosome therapeutic market and accounts for the highest market share in 2018 which is followed by EXOCOBIO. The other key players existing in the market evox THERAPEUTICS, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC. among others.

Coloplast Corp

Stem Cells Group headquartered in Florida, U.S was founded in 2010. The company is engaged in research and developed of stem cells technology to provide various therapies and treatments. The company is providing training, equipment, laboratory, network, therapies. The market focus products lie under therapies category. The company is continuously engaged in manufacturing and developments of exosome therapeutic.

In June 2019, Stem Cells Group has expanded its new stem cell offices in Valencia, Spain and Cochabamba, Bolivia. The expansion of new clinics will help the company to increase its market presence in Europe.

It has its global networks through direct sales representatives and distributors in North America.

EXOCOBIO

EXOCOBIO focuses on the stem cell-derived exosomes to develop innovative therapeutic and cosmetic products. The company is providing products in ASC-Exosome for cosmeceuticals - Natural Exosome, VEXOSOME -Adipose Tissue Regeneration Exosome. The market focus products are ASC-Exosome for cosmeceuticals - Natural Exosome, VEXOSOME -Adipose Tissue Regeneration Exosome. The company is engaged in providing exosome therapeutic.

In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

It has its global networks through direct sales representatives and distributors in South Korea

Recent Strategic Decisions